Key features and details
- GluN2D (formerly NR2D) antagonist, with some subunit selectivity
- CAS Number: 344768-30-5
- Purity: > 98%
- Soluble in 2 eq. NaOH to 50 mM (with warming)
- Form / State: Solid
- Source: Synthetic
Product nameUBP141, GluN2D antagonist
DescriptionGluN2D (formerly NR2D) antagonist, with some subunit selectivity
GluN2D (formerly NR2D) antagonist, displaying modest GluN2 (NR2) subunit selectivity. Shows 7-fold selectivity for GluN2D (NR2D)-containing NMDA receptors vs. GluN2B (NR2B) and 5-fold selectivity over GluN2A (NR2A ) but does not discriminate between GluN2C (NR2C) and GluN2D (NR2D). Ki values are 22 (NR1/2A), 17.2 (NR1/2B), 5.24 (NR1/2C) and 2.36 μM (NR1/2D).
Chemical name(2R*,3S*)-1-(Phenanthrenyl-3-carbonyl)piperazine-2,3-dicarboxylic acid
Storage instructionsStore at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Solubility overviewSoluble in 2 eq. NaOH to 50 mM (with warming)
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab120193 has been referenced in 9 publications.
- Andrade-Talavera Y et al. Presynaptic Spike Timing-Dependent Long-Term Depression in the Mouse Hippocampus. Cereb Cortex 26:3637-54 (2016). PubMed: 27282393
- Lozovaya N et al. Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model. Nat Commun 5:4563 (2014). PubMed: 25081057
- De Bundel D et al. Hippocampal and prefrontal dopamine D1/5 receptor involvement in the memory-enhancing effect of reboxetine. Int J Neuropsychopharmacol 16:2041-51 (2013). WB ; Rat . PubMed: 23672849
- Yamamoto H et al. Involvement of the N-methyl-D-aspartate receptor GluN2D subunit in phencyclidine-induced motor impairment, gene expression, and increased Fos immunoreactivity. Mol Brain 6:56 (2013). PubMed: 24330819
- Larsen RS et al. NR3A-containing NMDARs promote neurotransmitter release and spike timing-dependent plasticity. Nat Neurosci 14:338-44 (2011). PubMed: 21297630
- Palygin O et al. Distinct pharmacological and functional properties of NMDA receptors in mouse cortical astrocytes. Br J Pharmacol 163:1755-66 (2011). PubMed: 21449975
- Pregno G et al. Neuregulin1/ErbB4-induced migration in ST14A striatal progenitors: calcium-dependent mechanisms and modulation by NMDA receptor activation. BMC Neurosci 12:103 (2011). PubMed: 21991932
- Banerjee A et al. Double dissociation of spike timing-dependent potentiation and depression by subunit-preferring NMDA receptor antagonists in mouse barrel cortex. Cereb Cortex 19:2959-69 (2009). PubMed: 19363149
- Hu NW et al. GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo. Proc Natl Acad Sci U S A 106:20504-9 (2009). PubMed: 19918059